173 related articles for article (PubMed ID: 38424218)
1. Dual-inhibition of NAMPT and PAK4 induces anti-tumor effects in 3D-spheroids model of platinum-resistant ovarian cancer.
Kudo K; Greer YE; Yoshida T; Harrington BS; Korrapati S; Shibuya Y; Henegar L; Kopp JB; Fujii T; Lipkowitz S; Annunziata CM
Cancer Gene Ther; 2024 May; 31(5):721-735. PubMed ID: 38424218
[TBL] [Abstract][Full Text] [Related]
2. Dual and Specific Inhibition of NAMPT and PAK4 By KPT-9274 Decreases Kidney Cancer Growth.
Abu Aboud O; Chen CH; Senapedis W; Baloglu E; Argueta C; Weiss RH
Mol Cancer Ther; 2016 Sep; 15(9):2119-29. PubMed ID: 27390344
[TBL] [Abstract][Full Text] [Related]
3. PAK4-NAMPT Dual Inhibition as a Novel Strategy for Therapy Resistant Pancreatic Neuroendocrine Tumors.
Mpilla G; Aboukameel A; Muqbil I; Kim S; Beydoun R; Philip PA; Mohammad RM; Kamgar M; Shidham V; Senapedis W; Baloglu E; Li J; Dyson G; Xue Y; El-Rayes B; Azmi AS
Cancers (Basel); 2019 Nov; 11(12):. PubMed ID: 31795447
[TBL] [Abstract][Full Text] [Related]
4. Targeting the vulnerability to NAD
Takao S; Chien W; Madan V; Lin DC; Ding LW; Sun QY; Mayakonda A; Sudo M; Xu L; Chen Y; Jiang YY; Gery S; Lill M; Park E; Senapedis W; Baloglu E; Müschen M; Koeffler HP
Leukemia; 2018 Mar; 32(3):616-625. PubMed ID: 28904384
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme of the nicotinamide adenine dinucleotide (NAD) salvage pathway, to target glioma heterogeneity through mitochondrial oxidative stress.
Sharma P; Xu J; Williams K; Easley M; Elder JB; Lonser R; Lang FF; Lapalombella R; Sampath D; Puduvalli VK
Neuro Oncol; 2022 Feb; 24(2):229-244. PubMed ID: 34260721
[TBL] [Abstract][Full Text] [Related]
6. KPT-9274, an Inhibitor of PAK4 and NAMPT, Leads to Downregulation of mTORC2 in Triple Negative Breast Cancer Cells.
Cordover E; Wei J; Patel C; Shan NL; Gionco J; Sargsyan D; Wu R; Cai L; Kong AN; Jacinto E; Minden A
Chem Res Toxicol; 2020 Feb; 33(2):482-491. PubMed ID: 31876149
[TBL] [Abstract][Full Text] [Related]
7. PAK4 and NAMPT as Novel Therapeutic Targets in Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, and Mantle Cell Lymphoma.
Khan HY; Uddin MH; Balasubramanian SK; Sulaiman N; Iqbal M; Chaker M; Aboukameel A; Li Y; Senapedis W; Baloglu E; Mohammad RM; Zonder J; Azmi AS
Cancers (Basel); 2021 Dec; 14(1):. PubMed ID: 35008323
[TBL] [Abstract][Full Text] [Related]
8. Dual PAK4-NAMPT Inhibition Impacts Growth and Survival, and Increases Sensitivity to DNA-Damaging Agents in Waldenström Macroglobulinemia.
Li N; Lopez MA; Linares M; Kumar S; Oliva S; Martinez-Lopez J; Xu L; Xu Y; Perini T; Senapedis W; Baloglu E; Shammas MA; Hunter Z; Anderson KC; Treon SP; Munshi NC; Fulciniti M
Clin Cancer Res; 2019 Jan; 25(1):369-377. PubMed ID: 30206161
[TBL] [Abstract][Full Text] [Related]
9. NAMPT Inhibition Suppresses Cancer Stem-like Cells Associated with Therapy-Induced Senescence in Ovarian Cancer.
Nacarelli T; Fukumoto T; Zundell JA; Fatkhutdinov N; Jean S; Cadungog MG; Borowsky ME; Zhang R
Cancer Res; 2020 Feb; 80(4):890-900. PubMed ID: 31857293
[TBL] [Abstract][Full Text] [Related]
10. Anti-tumor NAMPT inhibitor, KPT-9274, mediates gender-dependent murine anemia and nephrotoxicity by regulating SIRT3-mediated SOD deacetylation.
Mitchell S; Zhang P; Cannon M; Beaver L; Lehman A; Harrington B; Sampath D; Byrd JC; Lapalombella R
J Hematol Oncol; 2021 Jun; 14(1):101. PubMed ID: 34187548
[TBL] [Abstract][Full Text] [Related]
11. Anticystogenic activity of a small molecule PAK4 inhibitor may be a novel treatment for autosomal dominant polycystic kidney disease.
Hwang VJ; Zhou X; Chen X; Trott J; Abu Aboud O; Shim K; Dionne LK; Chmiel KJ; Senapedis W; Baloglu E; Mahjoub MR; Li X; Weiss RH
Kidney Int; 2017 Oct; 92(4):922-933. PubMed ID: 28545714
[TBL] [Abstract][Full Text] [Related]
12. PAK4-NAMPT Dual Inhibition Sensitizes Pancreatic Neuroendocrine Tumors to Everolimus.
Mpilla GB; Uddin MH; Al-Hallak MN; Aboukameel A; Li Y; Kim SH; Beydoun R; Dyson G; Baloglu E; Senapedis WT; Landesman Y; Wagner KU; Viola NT; El-Rayes BF; Philip PA; Mohammad RM; Azmi AS
Mol Cancer Ther; 2021 Oct; 20(10):1836-1845. PubMed ID: 34253597
[TBL] [Abstract][Full Text] [Related]
13. Targeting the NAD
Ye C; Qi L; Li X; Wang J; Yu J; Zhou B; Guo C; Chen J; Zheng S
Cell Commun Signal; 2020 Jan; 18(1):16. PubMed ID: 32005247
[TBL] [Abstract][Full Text] [Related]
14. Novel p21-Activated Kinase 4 (PAK4) Allosteric Modulators Overcome Drug Resistance and Stemness in Pancreatic Ductal Adenocarcinoma.
Aboukameel A; Muqbil I; Senapedis W; Baloglu E; Landesman Y; Shacham S; Kauffman M; Philip PA; Mohammad RM; Azmi AS
Mol Cancer Ther; 2017 Jan; 16(1):76-87. PubMed ID: 28062705
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) as a therapeutic strategy in cancer.
Sampath D; Zabka TS; Misner DL; O'Brien T; Dragovich PS
Pharmacol Ther; 2015 Jul; 151():16-31. PubMed ID: 25709099
[TBL] [Abstract][Full Text] [Related]
16. Both gain and loss of Nampt function promote pressure overload-induced heart failure.
Byun J; Oka SI; Imai N; Huang CY; Ralda G; Zhai P; Ikeda Y; Ikeda S; Sadoshima J
Am J Physiol Heart Circ Physiol; 2019 Oct; 317(4):H711-H725. PubMed ID: 31347918
[TBL] [Abstract][Full Text] [Related]
17. Review of various NAMPT inhibitors for the treatment of cancer.
Wei Y; Xiang H; Zhang W
Front Pharmacol; 2022; 13():970553. PubMed ID: 36160449
[TBL] [Abstract][Full Text] [Related]
18. Apoptosis induced by NAD depletion is inhibited by KN-93 in a CaMKII-independent manner.
Takeuchi M; Yamamoto T
Exp Cell Res; 2015 Jul; 335(1):62-7. PubMed ID: 26024774
[TBL] [Abstract][Full Text] [Related]
19. Selective targeting of NAMPT by KPT-9274 in acute myeloid leukemia.
Mitchell SR; Larkin K; Grieselhuber NR; Lai TH; Cannon M; Orwick S; Sharma P; Asemelash Y; Zhang P; Goettl VM; Beaver L; Mims A; Puduvalli VK; Blachly JS; Lehman A; Harrington B; Henderson S; Breitbach JT; Williams KE; Dong S; Baloglu E; Senapedis W; Kirschner K; Sampath D; Lapalombella R; Byrd JC
Blood Adv; 2019 Feb; 3(3):242-255. PubMed ID: 30692102
[TBL] [Abstract][Full Text] [Related]
20. Identification of novel resistance mechanisms to NAMPT inhibition via the de novo NAD
Guo J; Lam LT; Longenecker KL; Bui MH; Idler KB; Glaser KB; Wilsbacher JL; Tse C; Pappano WN; Huang TH
Biochem Biophys Res Commun; 2017 Sep; 491(3):681-686. PubMed ID: 28756225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]